

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2563)

NOTICE OF POSTPONEMENT OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) refers to the announcement of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) dated 11 March 2026 in relation to the meeting of the Board (the “**Board Meeting**”) proposed to be held on Wednesday, 25 March 2026 for the purposes of considering and approving, among other matters, (i) considering and, if thought fit, approving the consolidated annual results of the Company and its subsidiaries for the year ended 31 December 2025 (the “**Annual Results**”) and its publication; (ii) considering the payment of a final dividend, if any; and (iii) transacting any other business.

The Board wishes to announce that since additional time is required for the Company and its auditor to review and finalise the Annual Results, the date of the Board Meeting will be postponed from Wednesday, 25 March 2026 to Monday, 30 March 2026.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 24 March 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.